EUCTR2009-016713-20-GB进行中（未招募）1 期
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder.A randomised, double-blind, placebo-controlled, parallel groups, international study.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- out patients, male or female, aged between 18 (or legal age for majority in the country) and 65 years inclusive
- •- primary diagnosis of Obsessive Compulsive Disorder according to DSM-IV-TR
- •- Y-BOCS total score = 20
- •- requiring a treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- women of childbearing potential without effective contraception as well as pregnant or breathfeeding women
- •- exclusive hoarders
- •- early onset OCD: diagnosed by a psychiatrist and treated before the age of 12
- •- severe or uncontrolled organic diseases, likely to interfere with the conduct of the study
- •- mental retardation or any pervasive developmental disorder
- •- hepatic impairment
- •- current diagnosis of neurological disorders
研究者
相似试验
进行中（未招募）
不适用
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder. A randomised, double-blind, placebo-controlled, parallel groups, international study. - NDMedDRA version: 12.1Level: LLTClassification code 10029898Term: Obsessive-compulsive disorderObsessive-compulsive disorderEUCTR2009-016713-20-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER80
尚未招募
2 期
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder.A randomised, double-blind, placebo-controlled, parallel groups, international study.psychiatrische en obsessieve en compulsieve stoornissenObsessive Compulsive DisorderNL-OMON34855Servier R&D Benelux15
进行中（未招募）
不适用
Efficacy of agomelatine in Patients with Obsessive-Compulsive DisorderMedDRA version: 14.1Level: PTClassification code 10029898Term: Obsessive-compulsive disorderSystem Organ Class: 10037175 - Psychiatric disordersObsessive-compulsive disorderEUCTR2009-016713-20-SEInstitut de recherches Internationales Servier80
进行中（未招募）
不适用
Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind international study with parallel groups versus sertraline (50 mg/day with potential adjustment to 100 mg). Six-week treatment plus optional continuation for 18 weeks.MedDRA version: 3.3Level: P.T.Classification code 10025453Major Depressive DisorderEUCTR2004-004009-10-ATInstitut de Recherches Internationales Servier300
进行中（未招募）
1 期
Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind international study with parallel groups versus sertraline (50 mg/day with potential adjustment to 100 mg). Six-week treatment plus optional continuation for 18 weeks.MedDRA version: 3.3Level: P.T.Classification code 10025453Major Depressive DisorderEUCTR2004-004009-10-ESInstitut de Recherches Internationales Servier300